We are in the business of excellent clinical evidence. EMA wants to partner with stakeholders, including those from industry, to drive up the quality of evidence…
In Conversation
We need to engage more, explain the system, and clarify the steps that we are taking
What does AI really mean? How can we make the equipment safe? The solution will be to start with low hanging fruit where risk is low…
Our motto is simple yet ambitious—everything for everyone, everywhere. I wish for peace, health, and reflection on our shared humanity in these challenging times
We aim to positively surprise our customers and partners with innovative approaches
It's important not to forget the significant contributions made by the pharmaceutical industry during the pandemic. The promises and commitments made by industry players and governments…
While generics continue to be a core focus, there has been a strategic shift towards emphasising innovation
Leveraging this resource [the Systeme National des Donnees de Sante (SNDS)], we conduct numerous real-world studies, positioning France among the leaders in real-world evidence generation within…
[We must] avoid placing AI at the centre and then working backwards to find a problem. Instead, we should take a problem-centric approach, identifying real-world challenges…
The funding landscape for science in Portugal is facing challenges that stem from a decrease in overall investment and shifting priorities. Despite the evident role of…
Our broad, global portfolio includes products that help treat the top 10 leading causes of death globally, as determined by the WHO
We are committed to finding a balanced approach that considers both the imperative of enabling better health outcomes and the need for ensuring the sustainability of…
